Polaryx Therapeutics PLYX
NASDAQ PLYX
$2.08 +0.06 (+2.97%)
At close: Oct 2, 2026 · 4:00 PM EDT

Polaryx Therapeutics (PLYX) Net Income towards Common Stockholders (2025 - 2026)

Updated

Polaryx Therapeutics' Net Income towards Common Stockholders came in at -$1.38 million for Q2 2026, compared with -$1.01 million a year earlier.

Analysis

Polaryx Therapeutics (PLYX) Net Income towards Common Stockholders (2025 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Polaryx Therapeutics reported Net Income towards Common Stockholders of -$9.98 million; for FY2025, it came in at -$9 million.

  • Going back by year, Net Income towards Common Stockholders was -$30.4 million in FY2024.
  • The five-year range for quarterly Net Income towards Common Stockholders is -$5.05 million (Q1 2025) to -$1.01 million (Q2 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 5.53 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 3.61 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 2.89 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -10.50 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -248.00 Mn
10 Polaryx Therapeutics 103.68 Mn 79.29 Mn - -1.38 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.38 Mn
Mar 31, 2026 -2.54 Mn
Jun 30, 2025 -1.01 Mn
Mar 31, 2025 -5.05 Mn
API Access

Polaryx Therapeutics Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=PLYX&period=max&api_key=YOUR_API_KEY